Pharmaron Beijing Co (300759.SZ) Stock Price
Pharmaron Beijing Co Price
Over the last 11 years Pharmaron Beijing Co grew revenue by 29.9% annually, reaching 14.10 B CNY. Earnings per share have grown at 48.8% per year over the last 11 years. For Pharmaron Beijing Co, the net margin of 11.8% is down versus 22.3% a few years ago. At today's price the dividend yield works out to roughly 0.43%. The payout ratio is around 21% of earnings. The dividend has grown at 26.5% per year over the past 6 years. The consensus 12-month price target for Pharmaron Beijing Co is 39.27 CNY, about 15.4% below where the stock trades today. Of 16 analysts, 11 rate the stock a buy — an overall Buy consensus.
Pharmaron Beijing Co stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Pharmaron Beijing Co business model & stock analysis
Frequently asked questions about Pharmaron Beijing Co
Analysts currently set an average price target of 37.70 CNY for the Pharmaron Beijing Co stock (median: 39.27 CNY), implying -18.8 % versus the latest price. The consensus is based on 16 analyst ratings.
16 analysts currently rate the Pharmaron Beijing Co stock: 11 recommend buying, 3 holding and 2 selling. For 2026, analysts expect Pharmaron Beijing Co to generate revenue of 16.72 B CNY and earnings per share of 1.09 CNY.
Converted at the current exchange rate, the Pharmaron Beijing Co share trades at 6.19 EUR (46.41 CNY).
The Pharmaron Beijing Co share (300759.SZ) is listed on 1 stock exchanges, including: Shenzhen (300759.SZ).
The expected revenue of Pharmaron Beijing Co is 16.72 B CNY. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Pharmaron Beijing Co is 1.93 B CNY. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Pharmaron Beijing Co is currently 42.50. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Pharmaron Beijing Co stock.
The price-to-sales ratio (P/S) of Pharmaron Beijing Co is currently 4.90. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Pharmaron Beijing Co stock.
The Eulerpool Quality Score for Pharmaron Beijing Co is 8/10.
The ISIN of Pharmaron Beijing Co is CNE100003JW4. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Pharmaron Beijing Co is 300759.SZ. The ticker symbol is used to trade Pharmaron Beijing Co shares on the stock exchange.
Pharmaron Beijing Co stock
Pharmaron Beijing Co Peer Group
Pharmaron Beijing Co Ticker
Pharmaron Beijing Co FIGI
All fundamentals and in-depth analysis of Pharmaron Beijing Co
Our stock analysis for Pharmaron Beijing Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pharmaron Beijing Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.